 | • レポートコード：QYR2104Z3080 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、不活化ワクチンのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（子供、大人）、用途別市場規模（病院、医療センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・不活化ワクチンの市場動向 ・企業の競争状況、市場シェア ・不活化ワクチンの種類別市場規模（子供、大人） ・不活化ワクチンの用途別市場規模（病院、医療センター） ・不活化ワクチンの北米市場規模2016-2027（アメリカ、カナダ） ・不活化ワクチンのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・不活化ワクチンのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・不活化ワクチンの中南米市場規模2016-2027（メキシコ、ブラジル） ・不活化ワクチンの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Astellas Pharma (Japan)、CSL Limited (Australia)、Emergent BioSolutions (U.S.)、GlaxoSmithKline (U.K.)、Johnson & Johnson (U.S.)、MedImmune (U.S.)、Merck & Co (U.S.)、Pfizer (U.S.)、Sanofi Pasteur (France)、Serum Institute of India Pvt (India)） ・結論 |
Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
Market Analysis and Insights: Global Inactivated Vaccine Market
The global Inactivated Vaccine market size is projected to reach US$ 7303 million by 2026, from US$ 5785.3 million in 2019, at a CAGR of 3.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Inactivated Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Inactivated Vaccine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Inactivated Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Inactivated Vaccine market.
Global Inactivated Vaccine Scope and Market Size
Inactivated Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Inactivated Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Children
Adult
Segment by Application
Hospital
Medical Center
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Astellas Pharma (Japan)
CSL Limited (Australia)
Emergent BioSolutions (U.S.)
GlaxoSmithKline (U.K.)
Johnson & Johnson (U.S.)
MedImmune (U.S.)
Merck & Co (U.S.)
Pfizer (U.S.)
Sanofi Pasteur (France)
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Inactivated Vaccine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Children
1.2.3 Adult
1.3 Market by Application
1.3.1 Global Inactivated Vaccine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Medical Center
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Inactivated Vaccine Market Perspective (2016-2027)
2.2 Inactivated Vaccine Growth Trends by Regions
2.2.1 Inactivated Vaccine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Inactivated Vaccine Historic Market Share by Regions (2016-2021)
2.2.3 Inactivated Vaccine Forecasted Market Size by Regions (2022-2027)
2.3 Inactivated Vaccine Industry Dynamic
2.3.1 Inactivated Vaccine Market Trends
2.3.2 Inactivated Vaccine Market Drivers
2.3.3 Inactivated Vaccine Market Challenges
2.3.4 Inactivated Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Inactivated Vaccine Players by Revenue
3.1.1 Global Top Inactivated Vaccine Players by Revenue (2016-2021)
3.1.2 Global Inactivated Vaccine Revenue Market Share by Players (2016-2021)
3.2 Global Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Inactivated Vaccine Revenue
3.4 Global Inactivated Vaccine Market Concentration Ratio
3.4.1 Global Inactivated Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Inactivated Vaccine Revenue in 2020
3.5 Inactivated Vaccine Key Players Head office and Area Served
3.6 Key Players Inactivated Vaccine Product Solution and Service
3.7 Date of Enter into Inactivated Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Inactivated Vaccine Breakdown Data by Type
4.1 Global Inactivated Vaccine Historic Market Size by Type (2016-2021)
4.2 Global Inactivated Vaccine Forecasted Market Size by Type (2022-2027)
5 Inactivated Vaccine Breakdown Data by Application
5.1 Global Inactivated Vaccine Historic Market Size by Application (2016-2021)
5.2 Global Inactivated Vaccine Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Inactivated Vaccine Market Size (2016-2027)
6.2 North America Inactivated Vaccine Market Size by Type
6.2.1 North America Inactivated Vaccine Market Size by Type (2016-2021)
6.2.2 North America Inactivated Vaccine Market Size by Type (2022-2027)
6.2.3 North America Inactivated Vaccine Market Size by Type (2016-2027)
6.3 North America Inactivated Vaccine Market Size by Application
6.3.1 North America Inactivated Vaccine Market Size by Application (2016-2021)
6.3.2 North America Inactivated Vaccine Market Size by Application (2022-2027)
6.3.3 North America Inactivated Vaccine Market Size by Application (2016-2027)
6.4 North America Inactivated Vaccine Market Size by Country
6.4.1 North America Inactivated Vaccine Market Size by Country (2016-2021)
6.4.2 North America Inactivated Vaccine Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Inactivated Vaccine Market Size (2016-2027)
7.2 Europe Inactivated Vaccine Market Size by Type
7.2.1 Europe Inactivated Vaccine Market Size by Type (2016-2021)
7.2.2 Europe Inactivated Vaccine Market Size by Type (2022-2027)
7.2.3 Europe Inactivated Vaccine Market Size by Type (2016-2027)
7.3 Europe Inactivated Vaccine Market Size by Application
7.3.1 Europe Inactivated Vaccine Market Size by Application (2016-2021)
7.3.2 Europe Inactivated Vaccine Market Size by Application (2022-2027)
7.3.3 Europe Inactivated Vaccine Market Size by Application (2016-2027)
7.4 Europe Inactivated Vaccine Market Size by Country
7.4.1 Europe Inactivated Vaccine Market Size by Country (2016-2021)
7.4.2 Europe Inactivated Vaccine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Inactivated Vaccine Market Size (2016-2027)
8.2 Asia-Pacific Inactivated Vaccine Market Size by Type
8.2.1 Asia-Pacific Inactivated Vaccine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Inactivated Vaccine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Inactivated Vaccine Market Size by Type (2016-2027)
8.3 Asia-Pacific Inactivated Vaccine Market Size by Application
8.3.1 Asia-Pacific Inactivated Vaccine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Inactivated Vaccine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Inactivated Vaccine Market Size by Application (2016-2027)
8.4 Asia-Pacific Inactivated Vaccine Market Size by Region
8.4.1 Asia-Pacific Inactivated Vaccine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Inactivated Vaccine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Inactivated Vaccine Market Size (2016-2027)
9.2 Latin America Inactivated Vaccine Market Size by Type
9.2.1 Latin America Inactivated Vaccine Market Size by Type (2016-2021)
9.2.2 Latin America Inactivated Vaccine Market Size by Type (2022-2027)
9.2.3 Latin America Inactivated Vaccine Market Size by Type (2016-2027)
9.3 Latin America Inactivated Vaccine Market Size by Application
9.3.1 Latin America Inactivated Vaccine Market Size by Application (2016-2021)
9.3.2 Latin America Inactivated Vaccine Market Size by Application (2022-2027)
9.3.3 Latin America Inactivated Vaccine Market Size by Application (2016-2027)
9.4 Latin America Inactivated Vaccine Market Size by Country
9.4.1 Latin America Inactivated Vaccine Market Size by Country (2016-2021)
9.4.2 Latin America Inactivated Vaccine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Inactivated Vaccine Market Size (2016-2027)
10.2 Middle East & Africa Inactivated Vaccine Market Size by Type
10.2.1 Middle East & Africa Inactivated Vaccine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Inactivated Vaccine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Inactivated Vaccine Market Size by Type (2016-2027)
10.3 Middle East & Africa Inactivated Vaccine Market Size by Application
10.3.1 Middle East & Africa Inactivated Vaccine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Inactivated Vaccine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Inactivated Vaccine Market Size by Application (2016-2027)
10.4 Middle East & Africa Inactivated Vaccine Market Size by Country
10.4.1 Middle East & Africa Inactivated Vaccine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Inactivated Vaccine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Astellas Pharma (Japan)
11.1.1 Astellas Pharma (Japan) Company Details
11.1.2 Astellas Pharma (Japan) Business Overview
11.1.3 Astellas Pharma (Japan) Inactivated Vaccine Introduction
11.1.4 Astellas Pharma (Japan) Revenue in Inactivated Vaccine Business (2016-2021)
11.1.5 Astellas Pharma (Japan) Recent Development
11.2 CSL Limited (Australia)
11.2.1 CSL Limited (Australia) Company Details
11.2.2 CSL Limited (Australia) Business Overview
11.2.3 CSL Limited (Australia) Inactivated Vaccine Introduction
11.2.4 CSL Limited (Australia) Revenue in Inactivated Vaccine Business (2016-2021)
11.2.5 CSL Limited (Australia) Recent Development
11.3 Emergent BioSolutions (U.S.)
11.3.1 Emergent BioSolutions (U.S.) Company Details
11.3.2 Emergent BioSolutions (U.S.) Business Overview
11.3.3 Emergent BioSolutions (U.S.) Inactivated Vaccine Introduction
11.3.4 Emergent BioSolutions (U.S.) Revenue in Inactivated Vaccine Business (2016-2021)
11.3.5 Emergent BioSolutions (U.S.) Recent Development
11.4 GlaxoSmithKline (U.K.)
11.4.1 GlaxoSmithKline (U.K.) Company Details
11.4.2 GlaxoSmithKline (U.K.) Business Overview
11.4.3 GlaxoSmithKline (U.K.) Inactivated Vaccine Introduction
11.4.4 GlaxoSmithKline (U.K.) Revenue in Inactivated Vaccine Business (2016-2021)
11.4.5 GlaxoSmithKline (U.K.) Recent Development
11.5 Johnson & Johnson (U.S.)
11.5.1 Johnson & Johnson (U.S.) Company Details
11.5.2 Johnson & Johnson (U.S.) Business Overview
11.5.3 Johnson & Johnson (U.S.) Inactivated Vaccine Introduction
11.5.4 Johnson & Johnson (U.S.) Revenue in Inactivated Vaccine Business (2016-2021)
11.5.5 Johnson & Johnson (U.S.) Recent Development
11.6 MedImmune (U.S.)
11.6.1 MedImmune (U.S.) Company Details
11.6.2 MedImmune (U.S.) Business Overview
11.6.3 MedImmune (U.S.) Inactivated Vaccine Introduction
11.6.4 MedImmune (U.S.) Revenue in Inactivated Vaccine Business (2016-2021)
11.6.5 MedImmune (U.S.) Recent Development
11.7 Merck & Co (U.S.)
11.7.1 Merck & Co (U.S.) Company Details
11.7.2 Merck & Co (U.S.) Business Overview
11.7.3 Merck & Co (U.S.) Inactivated Vaccine Introduction
11.7.4 Merck & Co (U.S.) Revenue in Inactivated Vaccine Business (2016-2021)
11.7.5 Merck & Co (U.S.) Recent Development
11.8 Pfizer (U.S.)
11.8.1 Pfizer (U.S.) Company Details
11.8.2 Pfizer (U.S.) Business Overview
11.8.3 Pfizer (U.S.) Inactivated Vaccine Introduction
11.8.4 Pfizer (U.S.) Revenue in Inactivated Vaccine Business (2016-2021)
11.8.5 Pfizer (U.S.) Recent Development
11.9 Sanofi Pasteur (France)
11.9.1 Sanofi Pasteur (France) Company Details
11.9.2 Sanofi Pasteur (France) Business Overview
11.9.3 Sanofi Pasteur (France) Inactivated Vaccine Introduction
11.9.4 Sanofi Pasteur (France) Revenue in Inactivated Vaccine Business (2016-2021)
11.9.5 Sanofi Pasteur (France) Recent Development
11.10 Serum Institute of India Pvt (India)
11.10.1 Serum Institute of India Pvt (India) Company Details
11.10.2 Serum Institute of India Pvt (India) Business Overview
11.10.3 Serum Institute of India Pvt (India) Inactivated Vaccine Introduction
11.10.4 Serum Institute of India Pvt (India) Revenue in Inactivated Vaccine Business (2016-2021)
11.10.5 Serum Institute of India Pvt (India) Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Inactivated Vaccine Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Children
Table 3. Key Players of Adult
Table 4. Global Inactivated Vaccine Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Inactivated Vaccine Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Inactivated Vaccine Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Inactivated Vaccine Market Share by Regions (2016-2021)
Table 8. Global Inactivated Vaccine Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Inactivated Vaccine Market Share by Regions (2022-2027)
Table 10. Inactivated Vaccine Market Trends
Table 11. Inactivated Vaccine Market Drivers
Table 12. Inactivated Vaccine Market Challenges
Table 13. Inactivated Vaccine Market Restraints
Table 14. Global Inactivated Vaccine Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Inactivated Vaccine Market Share by Players (2016-2021)
Table 16. Global Top Inactivated Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Inactivated Vaccine as of 2020)
Table 17. Ranking of Global Top Inactivated Vaccine Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Inactivated Vaccine Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Inactivated Vaccine Product Solution and Service
Table 21. Date of Enter into Inactivated Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Inactivated Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Inactivated Vaccine Revenue Market Share by Type (2016-2021)
Table 25. Global Inactivated Vaccine Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Inactivated Vaccine Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Inactivated Vaccine Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Inactivated Vaccine Revenue Market Share by Application (2016-2021)
Table 29. Global Inactivated Vaccine Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Inactivated Vaccine Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Inactivated Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Inactivated Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Inactivated Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Inactivated Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Inactivated Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Inactivated Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Inactivated Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Inactivated Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Inactivated Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Inactivated Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Inactivated Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Inactivated Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Inactivated Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Inactivated Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Inactivated Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Inactivated Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Inactivated Vaccine Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Inactivated Vaccine Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Inactivated Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Inactivated Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Inactivated Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Inactivated Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Inactivated Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Inactivated Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Inactivated Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Inactivated Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Inactivated Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Inactivated Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Inactivated Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Inactivated Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 61. Astellas Pharma (Japan) Company Details
Table 62. Astellas Pharma (Japan) Business Overview
Table 63. Astellas Pharma (Japan) Inactivated Vaccine Product
Table 64. Astellas Pharma (Japan) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 65. Astellas Pharma (Japan) Recent Development
Table 66. CSL Limited (Australia) Company Details
Table 67. CSL Limited (Australia) Business Overview
Table 68. CSL Limited (Australia) Inactivated Vaccine Product
Table 69. CSL Limited (Australia) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 70. CSL Limited (Australia) Recent Development
Table 71. Emergent BioSolutions (U.S.) Company Details
Table 72. Emergent BioSolutions (U.S.) Business Overview
Table 73. Emergent BioSolutions (U.S.) Inactivated Vaccine Product
Table 74. Emergent BioSolutions (U.S.) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 75. Emergent BioSolutions (U.S.) Recent Development
Table 76. GlaxoSmithKline (U.K.) Company Details
Table 77. GlaxoSmithKline (U.K.) Business Overview
Table 78. GlaxoSmithKline (U.K.) Inactivated Vaccine Product
Table 79. GlaxoSmithKline (U.K.) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 80. GlaxoSmithKline (U.K.) Recent Development
Table 81. Johnson & Johnson (U.S.) Company Details
Table 82. Johnson & Johnson (U.S.) Business Overview
Table 83. Johnson & Johnson (U.S.) Inactivated Vaccine Product
Table 84. Johnson & Johnson (U.S.) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 85. Johnson & Johnson (U.S.) Recent Development
Table 86. MedImmune (U.S.) Company Details
Table 87. MedImmune (U.S.) Business Overview
Table 88. MedImmune (U.S.) Inactivated Vaccine Product
Table 89. MedImmune (U.S.) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 90. MedImmune (U.S.) Recent Development
Table 91. Merck & Co (U.S.) Company Details
Table 92. Merck & Co (U.S.) Business Overview
Table 93. Merck & Co (U.S.) Inactivated Vaccine Product
Table 94. Merck & Co (U.S.) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 95. Merck & Co (U.S.) Recent Development
Table 96. Pfizer (U.S.) Company Details
Table 97. Pfizer (U.S.) Business Overview
Table 98. Pfizer (U.S.) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 99. Pfizer (U.S.) Recent Development
Table 100. Sanofi Pasteur (France) Company Details
Table 101. Sanofi Pasteur (France) Business Overview
Table 102. Sanofi Pasteur (France) Inactivated Vaccine Product
Table 103. Sanofi Pasteur (France) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 104. Sanofi Pasteur (France) Recent Development
Table 105. Serum Institute of India Pvt (India) Company Details
Table 106. Serum Institute of India Pvt (India) Business Overview
Table 107. Serum Institute of India Pvt (India) Inactivated Vaccine Product
Table 108. Serum Institute of India Pvt (India) Revenue in Inactivated Vaccine Business (2016-2021) & (US$ Million)
Table 109. Serum Institute of India Pvt (India) Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Inactivated Vaccine Market Share by Type: 2020 VS 2027
Figure 2. Children Features
Figure 3. Adult Features
Figure 4. Global Inactivated Vaccine Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Medical Center Case Studies
Figure 7. Inactivated Vaccine Report Years Considered
Figure 8. Global Inactivated Vaccine Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Inactivated Vaccine Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Inactivated Vaccine Market Share by Regions: 2020 VS 2027
Figure 11. Global Inactivated Vaccine Market Share by Regions (2022-2027)
Figure 12. Global Inactivated Vaccine Market Share by Players in 2020
Figure 13. Global Top Inactivated Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Inactivated Vaccine as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Inactivated Vaccine Revenue in 2020
Figure 15. Global Inactivated Vaccine Revenue Market Share by Type (2016-2021)
Figure 16. Global Inactivated Vaccine Revenue Market Share by Type (2022-2027)
Figure 17. North America Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Inactivated Vaccine Market Share by Type (2016-2027)
Figure 19. North America Inactivated Vaccine Market Share by Application (2016-2027)
Figure 20. North America Inactivated Vaccine Market Share by Country (2016-2027)
Figure 21. United States Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Inactivated Vaccine Market Share by Type (2016-2027)
Figure 25. Europe Inactivated Vaccine Market Share by Application (2016-2027)
Figure 26. Europe Inactivated Vaccine Market Share by Country (2016-2027)
Figure 27. Germany Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Inactivated Vaccine Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Inactivated Vaccine Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Inactivated Vaccine Market Share by Region (2016-2027)
Figure 37. China Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Inactivated Vaccine Market Share by Type (2016-2027)
Figure 45. Latin America Inactivated Vaccine Market Share by Application (2016-2027)
Figure 46. Latin America Inactivated Vaccine Market Share by Country (2016-2027)
Figure 47. Mexico Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Inactivated Vaccine Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Inactivated Vaccine Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Inactivated Vaccine Market Share by Country (2016-2027)
Figure 53. Turkey Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Inactivated Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Astellas Pharma (Japan) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 57. CSL Limited (Australia) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 58. Emergent BioSolutions (U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 59. GlaxoSmithKline (U.K.) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 60. Johnson & Johnson (U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 61. MedImmune (U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 62. Merck & Co (U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 63. Pfizer (U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 64. Sanofi Pasteur (France) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 65. Serum Institute of India Pvt (India) Revenue Growth Rate in Inactivated Vaccine Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
世界のダニ媒介性脳炎不活化ワクチン市場 2021：企業別、地域別、種類・用途別 The Tick-borne Encephalitis Inactivated Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiz…- 世界の食用ワクチン市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Edible Vaccine Market The global Edible Vaccine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brill…
- 世界の食用ワクチン市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Edible Vaccine Market The global Edible Vaccine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brill…
- 世界の新型コロナウイルス感染症RNAワクチン市場規模・現状・予測（2021年-2027年） RNA vaccines are leading the way in vaccines because they are particularly well suited to rapid development.Although no RNA vaccine has yet been approved, the threat of a pandemic is a great incentive to accelerate its progress.RNA vaccines consist of mrna strands.They are injected into the body, us…
- 世界の新型コロナウイルス感染症DNAワクチン市場規模・現状・予測（2021年-2027年） In 2021, the global COVID-19 DNA Vaccine market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. This report focuses on the global COVID-19 DNA Vaccine status, future forecast, growth opportunity, key market, and key play…